12
Nov
Nov 12 (Reuters) - Indian drugmaker Zydus Lifesciences (ZYDU.NS), opens new tabon Tuesday reported a 14% rose in second-quarter profit, helped by strong demand for generic drugs in its key United States and Indian markets.The company's consolidated net profit rose to 9.11 billion rupees ($107.93 million), in line with analysts' average estimate of 9.13 billion rupees, according to data compiled by LSEG.Its total revenue rose 20% to 52.37 billion rupees, boosted by a nearly 30% rise in its U.S. market and a 10% inflation in its India business. These two markets contribute about 85% of Zydus Life's total revenue.For more…